Oncology Research and Treatment · 2004 · 15 citations · 11 references
MedicineOncologyPharmacologyChemotherapyHypersensitivityThoracic OncologyHypersensitivity PneumonitisMalignant NeoplasmsPulmonary ToxicityPulmonary ToxicologyRespiratory DiseaseRespiratory ToxicologyAcute Hypersensitivity PneumonitisCancer Therapy-related Pulmonary ToxicityChemotherapy-induced Pulmonary ToxicityDrug-induced PneumonitisDrug-related PneumonitisPulmonary Parenchymal InjuryPulmonary Toxic InjuryTaxane-based Chemotherapy
BACKGROUND: Acute pulmonary toxicity in cancer patients treated with docetaxel has been reported in previous phase II studies and case reports. Unlike transient pulmonary infiltrates, it is demonstrated that docetaxel-induced interstitial pneumopathy is a severe clinical condition that generally leads to respiratory failure. CASE REPORT: We report a patient with breast cancer who received 2 cycles of docetaxel in 3-week intervals and developed respiratory failure. The clinical, pathologic, and radiographic data supported pulmonary toxicity caused by a hypersensitivity reaction to docetaxel as the most likely etiology. The patient developed the same symptoms and radiological findings after 1 cycle of paclitaxel administration. Unlike other more severe examples in the literature, this patient's condition did not require mechanical ventilation, and she recovered after corticosteroid treatment. CONCLUSION: The present case raises the possibility that taxanes, as a group of chemotherapeutic agents, may cause the same type of adverse reaction in the pulmonary parenchyma. The authors recommend that any patient who develops a taxane-induced pulmonary toxic reaction, not be rechallenged or treated with another agent of the same class.
11
A method for estimating the probability of adverse drug reactions
C. A. Naranjo, U. Busto, Edward M. Sellers et al. · Clinical Pharmacology & Therapeutics · 1981 · 11.6K citations
Docetaxel: an active drug for squamous cell carcinoma of the head and neck.
Arnon I. Dreyfuss, J. Clark, Charles M. Norris et al. · Journal of Clinical Oncology · 1996 · 233 citations
Medicine, Oncology, Pharmacology +12